Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12
| Autor: | Kotu T-Wrap Study Investigators, Toru Yoshioka, Yoshihisa Fujino, Akinori Sakai, Takeshi Sakata, Eiichiro Nakamura, Kenichiro Nakai, Hidehiro Matsumoto, Kenichiro Narusawa, Fumio Fukuda, Satoshi Ikeda |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Visual Analog Scale Visual analogue scale Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Drug Administration Schedule law.invention 03 medical and health sciences 0302 clinical medicine Endocrinology Lumbar Quality of life Randomized controlled trial law Bone Density Teriparatide medicine Humans Orthopedics and Sports Medicine Aged Bone mineral Aged 80 and over Alendronate Bone Density Conservation Agents business.industry General Medicine Low back pain Surgery Orthopedic surgery Quality of Life Spinal Fractures Female 030101 anatomy & morphology medicine.symptom business medicine.drug |
| Zdroj: | Journal of bone and mineral metabolism. 38(1) |
| ISSN: | 1435-5604 |
| Popis: | The objective of the present multicenter randomized study was to compare weekly teriparatide with alendronate in their inhibition of vertebral collapse, effects on delayed union, pain relief, and improvement of quality of life (QOL) in women with new osteoporotic vertebral fractures within 1 week after onset of the fracture. Patients were randomly allocated to the teriparatide and alendronate groups. Vertebral collapse, low back pain assessed by a visual analog scale, and QOL assessed by EuroQol 5 dimension at weeks 1, 2, 4, 8, and 12 after the start of the treatment were compared between the groups. Lumbar bone mineral density (BMD) at baseline and week 12 and the rate of delayed union at week 12 were also compared. Each group consisted of 48 subjects. Vertebral collapse progressed over time in both groups, with no significant difference between the groups. Pain on rising up from lying position, turning over in bed, and resting in the lying position improved over time in both groups, with no significant difference between the groups. There were no significant differences in increase in BMD and delayed union. QOL in the teriparatide group showed significant improvement in comparison with that in the alendronate group at week 12. The weekly formulation of teriparatide showed comparable inhibition of vertebral collapse, increase in BMD, promotion of bone union, and improvement of pain and significant improvement of QOL at week 12 in comparison with alendronate in patients with a new osteoporotic vertebral fracture within 1 week after onset of the fracture. The weekly formulation of teriparatide may have improved components of QOL other than pain at week 12. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink